news

CUPERTINO, Calif., Sep 2, 2003 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has completed validation of the terminal sterilization manufacturing process for its CHRONOGESIC (sufentanil) Pain Therapy product. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) “Our stated objectives this year were to implement some necessary design and manufacturing enhancements to our CHRONOGESIC product and […]

CUPERTINO, Calif., Aug. 5 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill — 23rd Annual Summer Seminar. The conference is being held at the Boston Marriott Long Wharf Hotel. James E. Brown, DVM, Chief Executive Officer, will be presenting at the conference on Wednesday, August

CUPERTINO, Calif., Jul 24, 2003 /PRNewswire-FirstCall via Comtex/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2003. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT’s net loss for the three months ended June 30, 2003 was $5.1 million or 10 cents per share, compared to $9.9 million or 21 cents per

CUPERTINO, Calif., Jul 11, 2003 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that the initial purchaser of $50 million of its 6.25% Convertible Notes due 2008 has elected to exercise its option to purchase an additional $10 million principal amount of such Notes. As a result, the final aggregate principal amount of

CUPERTINO, Calif., July 11 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2003 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, July 24, 2003 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive Officer, Tom

CUPERTINO, Calif., June 13 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it agreed to privately place $50 million aggregate principal amount of Convertible Notes due 2008. These Notes will be convertible into DURECT Corporation common stock at a conversion price of $3.15 per share (reflecting a premium of 25%, relative to the NASDAQ

CUPERTINO, Calif., June 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it proposes to offer a new issue of $50 million of Convertible Notes due 2008 through a Rule 144A offering to qualified institutional buyers. These notes will be convertible into DURECT common stock at a price to be determined. The Company has

CUPERTINO, Calif., June 10 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the Company has commenced clinical testing of its post-operative pain relief depot product. DURECT’s post-operative pain relief depot product, a sustained release injectible using the SABER(TM) delivery system and a local anesthetic, is designed to be administered locally around a surgical site

CUPERTINO, Calif., May 15, 2003 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Friedman Billings Ramsey 7th Annual Technology & Growth Investor Conference. The conference is being held at The Millennium Hotel in New York City. James E. Brown, DVM, Chief Executive Officer, will be presenting at

CUPERTINO, Calif., April 28 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2003. DURECT’s net loss for the three months ended March 31, 2003 was $5.9 million or 12 cents per share, compared to $9.7 million or 20 cents per share for the same period in